Apsen Farmaceutica SA

DUBLIN, Nov. 14, 2023 /PRNewswire/ -- The "Drug Delivery Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering. Drug Delivery Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the drug delivery deals entered into by the worlds leading biopharma companies. This report contains a comprehensive listing of 1551 drug delivery deals announced since 2016 including financial terms where available including links to online deal records of actual drug delivery partnering deals as disclosed by the deal parties. Fully revised and updated, the report provides details of drug delivery deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter drug delivery deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The initial chapters of this report provide an orientation of drug delivery dealmaking. The report also includes numerous table and figures that illustrate the trends and activities in drug delivery deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key benefits Understand deal trends since 2016 Browse drug delivery collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in drug delivery dealmaking 2.1. Introduction 2.2. Drug delivery deals over the years 2.3. Most active drug delivery dealmakers 2.4. Drug delivery deals by deal type 2.5. Drug delivery deals by therapy area 2.6. Drug delivery deals by industry sector 2.7. Deal terms for drug delivery deals 2.7.1 Drug delivery deals headline values 2.7.2 Drug delivery deal upfront payments 2.7.3 Drug delivery deal milestone payments 2.7.4 Drug delivery royalty rates Chapter 3 - Leading drug delivery deals 3.1. Introduction 3.2. Top drug delivery deals by value Chapter 4 - Most active drug delivery dealmakers 4.1. Introduction 4.2. Most active drug delivery dealmakers 4.3. Most active drug delivery deals company profiles Chapter 5 - Drug delivery contracts dealmaking directory 5.1. Introduction 5.2. Drug delivery contracts dealmaking directory Chapter 6 - Drug delivery dealmaking by technology type Deal directory Deal directory - Drug delivery deals by company A-Z Deal directory - Drug delivery deals by deal type Deal directory - Drug delivery deals by therapy area Companies Mentioned Delta 9 Cannabis Korea Advanced Institute of Science and Technology STADA Arzneimittel TFB & Associates Imbed Bio Sesen Bio Motif Bio Avior Bio Tetra Bio-Pharma Helix BioPharma Carna BioSciences AMPEL BioSolutions Leads Biolabs Orbit Biomedical Proxy Biomedical Dance Biopharm NEMUS Bioscience Artes Biotechnology Tamir Biotechnology Juyou Biotechnology Small Business Innovation Research Auxly Cannabis Group North Carolina State University Magle Chemoswed LatAm Clinical Trials Eve & Co Aceto Corporation Green Cross LabCell Nitto Denko Kwang Dong Pharmaceutical Rapid Dose Therapeutics Fidia Farmaceutici Apsen Farmacutica Grupo Ferrer Altus Formulation Aspen Global Eitan Group Clear Guide Medical Evero Health World Health Organization Bayer Healthcare For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets

DUBLIN, June 2, 2023 /PRNewswire/ -- The "Global Musculoskeletal Partnering 2016-2023: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. This report provides the full collection of musculoskeletal disease deals signed between the world's pharmaceutical and biotechnology companies since 2016. Trends in musculoskeletal partnering deals Financial deal terms for headline, upfront and royalty by stage of development Musculoskeletal partnering agreement structure Musculoskeletal partnering contract documents Top musculoskeletal deals by value Most active musculoskeletal dealmakers Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering musculoskeletal deals. The report presents financial deal terms values for musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. Report scope The report is intended to provide the reader with an in-depth understanding and access to musculoskeletal trends and structure of deals entered into by leading companies worldwide. Global Musculoskeletal Partnering 2016 to 2023 includes: Trends in musculoskeletal dealmaking in the biopharma industry since 2016 Access to headline, upfront, milestone and royalty data Access to hundreds of musculoskeletal deal contract documents Comprehensive access to over 600 musculoskeletal deal records The leading musculoskeletal deals by value since 2016 Most active musculoskeletal dealmakers since 2016 The report includes deals for the following indications: Arthritis, Ankylosing spondylitis, Juvenile arthritis, Osteoarthritis, Psoriatic arthritis, Rheumatoid arthritis, Bone fracture, Hip, Carpel tunnel syndrome, Frozen shoulder, Gout, Knee, Meniscus damage, Muscular dystrophy, Osteoporosis, Paget's disease, Spinal muscular atrophy, Bone pain, Back pain, Muscular pain, Stiffness, Weakness, plus other musculoskeletal indications. In Global Musculoskeletal Partnering 2016 to 2023, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Global Musculoskeletal Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are the sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in musculoskeletal dealmaking 2.1. Introduction 2.2. Musculoskeletal partnering over the years 2.3. Musculoskeletal partnering by deal type 2.4. Musculoskeletal partnering by industry sector 2.5. Musculoskeletal partnering by stage of development 2.6. Musculoskeletal partnering by technology type 2.7. Musculoskeletal partnering by therapeutic indication Chapter 3 -Financial deal terms for musculoskeletal partnering 3.1. Introduction 3.2. Disclosed financials terms for musculoskeletal partnering 3.3. Musculoskeletal partnering headline values 3.4. Musculoskeletal deal upfront payments 3.5. Musculoskeletal deal milestone payments 3.6. Musculoskeletal royalty rates Chapter 4 - Leading musculoskeletal deals and dealmakers 4.1. Introduction 4.2. Most active in musculoskeletal partnering 4.3. List of most active dealmakers in musculoskeletal 4.4. Top musculoskeletal deals by value Chapter 5 - Musculoskeletal contract document directory 5.1. Introduction 5.2. Musculoskeletal partnering deals where contract document available Chapter 6 - Musculoskeletal dealmaking by therapeutic target 6.1. Introduction 6.2. Deals by musculoskeletal therapeutic target Companies Mentioned 3D-Side 3SBio A2A Pharmaceuticals Aavis Pharmaceuticals Abarca Abbvie AbCellera AC Bioscience Accenture Actigraph Activbody Active Implants Adaptive Health Additive Orthopaedics Advanced Human Imaging AdventHealth Affinia Therapeutics AGC Asahi Glass AgNovos Healthcare AgomAb Therapeutics Akashi Therapeutics AKL Research and Development AlfaMed Aligos Therapeutics AliMed Alkem Laboratories Allergan AlloSource Almirall Alpine Immune Sciences Altamira Bio Altasciences Alvogen Alvotech Ambry Genetics Amedica Amend Surgical American Association of Neuromuscular & Electrodiagnostic Medicine Amgen Amneal Pharmaceuticals AMRA AMRA Medical Anagenesis Biotechnologies Analysis Group AnaMar Angelini Pharma Angers University Anika Therapeutics ANI Pharmaceuticals Antares Pharma Antibe Therapeutics Apexigen Apple Apsen Farmacutica Aptahem Aptorum Group Aralez Pharmaceuticals Aratana Therapeutics Aravive Biologics argenx ARK Crystal Arrowhead Pharmaceuticals Arthrex Arthrosi Therapeutics Artialis Asahi Kasei Ascendis Pharma AskAt Asklepios Biopharmaceutical Assertio Therapeutics Astellas Pharma AstraZeneca Athrotech Atnahs Pharma Audentes Therapeutics Aurinia Pharmaceuticals Australian Research Council Autotelic BIO Avalere Health Avanos Medical Aveta Biomics AveXis Avidity Biosciences Avion Pharmaceuticals AWB Schraubtechnik und Industriebedarf Axovant Gene Therapies Azellon Cell Therapeutics Aziyo Biologics Back-A-Line Bacterin International Baebies Bamboo Therapeutics Bauerfeind Baxalta Bayer Baylor College of Medicine Bazis NN BC Platforms Beijing Tide Pharmaceutical Benitec Biopharma Berg BGI BillionToOne Bio-Thera Solutions BioAge Labs BioCanRx Biocomposites Biogen BioGen Medical Biohaven Pharmaceuticals BioInvent BioMarin Pharmaceutical BioMed X Innovation Center BionX Medical Technologies BioPharma Forest Bioqube Ventures Bioservo Technologies Biosolution Biosplice Bioventus BioVinc Bison & Rose Blue Belt Technologies Blueprint Medicines Bodycad Boehringer Ingelheim Bone Biologics Bone Therapeutics Brickell Biotech Brigham and Women's Hospital Bristol-Myers Squibb BRM Extremities BSN Medical Burke Therapeutics c-LEcta California Institute for Biomedical Research California Institute for Regenerative Medicine Calimmune Calliditas Therapeutics Camargo Pharmaceutical Services Camber Spine Technologies Can-Fite BioPharma CANbridge Pharmaceuticals Cantargia Capricor Therapeutics Capsigen CareFirst BlueCross BlueShield Carlsmed Carna BioSciences CartiHeal Cartiva CAS Casper Pharma Catabasis Pharmaceuticals Catalyst Pharmaceuticals cbdMD Cedars-Sinai Medical Center Celgene Celltech Cellthera Pharma Cell Therapy Catapult Celltrion Cellular Biomedicine Cel Sci Centinel Spine Centogene Cerhum For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets